Evidence map›Paper›PMID 18779965›Full record

ArticleDer Pathologe2008

[Molecular diagnostic testing in gliomas].

M Hasselblatt

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Pathologe, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

M HasselblattInstitut für Neuropathologie, Universitätsklinikum Münster, Domagkstrasse 19, 48129, Münster, Deutschland. hasselblatt@uni-muenster.de
University Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glial tumours represent the majority of central nervous system tumours. Even though current therapy guidelines do not advocate the routine use of molecular markers for treatment decisions, the identification of prognostic markers and patient subgroups that may especially benefit from novel therapeutic options becomes increasingly important also outside the setting of clinical trials. This review summarizes methods and rationale for the use of the determination of 1p/19q loss, MGMT promoter methylation and tyrosine kinase receptor expression as diagnostic, prognostic and predictive markers in gliomas.

Indexed as

Biomarkers, TumorBrain NeoplasmsChromosome DeletionChromosomes, Human, Pair 1Chromosomes, Human, Pair 19GliomaHumansMolecular Diagnostic TechniquesPredictive Value of TestsPrognosisBiomarkers, Tumor

Identifiers

PMID18779965
OpenAlexW2143521455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.